Clinical Corner – A summary of recent advances in the field of Chronic Liver Diseases by beneficiary 3 (AOP)

• Portal hypertension in NAFLD (10 January 2022)

• Lipoprotein(a) levels are associated with liver fibrosis grade in patients with NAFLD (10 December 2021)

• The role of environment contaminants in the development of NAFLD (18 November 2021)

• The social media stigma of NAFLD (19 October 2021)

• Non-invasive tests for advanced fibrosis in patients with NAFLD (09 September 2021)

• Sweetened beverages consumption and NAFLD (21 July 2021)

• Specific patterns in NAFLD patients with HCC (25 May 2021)

• Controlled Attenuation Parameter (CAP) and its promising role in clinical practice (06 May 2021)

• NAFLD in lean patients (25 March 2021)

• Controlled Attenuation Parameter (CAP) and its promising role in clinical practice (05 March 2021)

• Sarcopenia and skeletal muscle dysfunction in patients with NAFLD (08 February 2021)

• The role of liver fibrosis in the new onset of metabolic comorbidities in patients with NAFLD (29 July 2020)

• From Nonalcoholic Fatty Liver to Metabolic – dysfunction associated Fatty Liver Disease (MAFLD) (22 June 2020)

• Global Burden of Chronic Liver Diseases: the role of Nonalcoholic Fatty Liver Disease (14 May 2020)